TKNO · Alpha Teknova, Inc.
$7.00
-0.21 (-2.91%)
At close · Aug 20
Market Cap
$379.31M
Shares
53.69M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$7.00
Open$7.13
Day$6.78–7.30
52W close$1.99–7.39
Avg vol 30d216K
Short int1.5M · 2.8% float · 17.0d
Short vol48%
Last earningsAug 5, 2026
DataJun 2021–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+72%
above
Price vs 50-day avg
+25%
above
RSI (14)
64
neutral
MACD trend
Positive
52-week position
93%
near high
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+35%
trailing
6-month return
+171%
trailing
YTD return
+84%
this year
Relative strength
+160%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.78% of float · ▼ -5.3% MoM · 17.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+7%
Y/Y
Gross margin
33%
expanding
EPS growth
+44%
Y/Y
Free cash flow
$-9.8M
Balance sheet
$7.3M
net debt
Quant / Vol
risk profile
Volatility
81%
annualized · 1-yr
Max drawdown
−69%
past year
ATR
7.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
fiscal year ending December 31, 2026
Total revenue
Initiated
$45M – $47M
prior FY $40.52M
midpoint +13.5% Y/Y
2026
Free Cash Outflow
Non-GAAP
up to $8M
Prior guidance
period ended
· from the Earnings Call filed Jun 30, 2024
Full year revenue
· full year 2024
$35M – $38M
Guided vs delivered
· last 2 settled
Total revenue
2024
guided $35M – $38M
$37.75M
In line
Total revenue
fiscal year 2023
guided $37M – $40M
$36.68M
Miss −4.7%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+72%
Bullish
Price vs 50-day avg
+25%
Bullish
RSI (14)
64
Neutral
MACD trend
Positive
Bullish
52-week position
93%
Bullish
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $6 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +12 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.78% of float · ▼ -5.3% MoM · 17.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
79 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $7 · 93%
Range high $7
vs 200-day avg +72%
vs 50-day avg +25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$2.69M | Six Months Ended June 30, 2026 | — |
| EBITDA non-GAAP | -$4.01M | Six Months Ended June 30, 2026 | — |
| Free Cash Flow non-GAAP | -$4.18M | Six Months Ended June 30, 2026 | — |
| Free Cash Outflow non-GAAP | $0.6M | the second quarter 2026 | — |
|
|
|||
| Number of Clinical Solutions customers | 25% | the full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TKNO
this stock
Alpha Teknova, Inc.
|
$379.31M | +84.2% | +7.4% | — | 2.8% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.85B | +16.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$50.24B | +1.7% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.41B | -2.4% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TKNO | -5.2% | +34.6% | +171.3% | +40.0% | +84.2% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -3.2% | +31.3% | +160.2% | +37.9% | +72.4% |
Key facts
CIK
1850902
CUSIP
02080L102
13F (30d)
74 filings
74 filers
Visit website
Investor relations